Four years into follow-up, the statistic that matters most for a pediatric brain tumor drug is how long children stay off treatment after stopping it. In the updated FIREFLY-1 analysis presented at SNO 2026 on November 14, the median time to next treatment across all 76 efficacy-evaluable patients reached 50.9 months, up from 42.6 months when the same trial reported at SNO 2025. That eight-month extension, in a population of children with relapsing BRAF-altered low-grade glioma, reflects a disease course that keeps shifting in favor of the drug the longer investigators watch.
The post-treatment observation data are where the picture gets clinically specific. Of the 41 patients who chose to enter the optional treatment-free period after completing 26 weekly cycles of tovorafenib, 54 percent remained off any therapy at two years and the median treatment-free interval has not yet been reached. Roughly half those patients (54 percent) did experience tumor rebound off treatment, and seven patients were retreated, of whom 11 received OJEMDA again. Nine of the 11 patients retreated with OJEMDA showed a smaller tumor at last scan than prior to retreatment, suggesting the drug retains activity on rechallenge, though the trial was not designed to test that formally., suggesting the drug retains activity on rechallenge, though the trial was not designed to test that formally.
The growth suppression signal, which has been a consistent concern with this class, produced a more reassuring long-term read. Among the 90 patients in the growth analysis set, 88 percent demonstrated growth recovery regardless of how much suppression occurred on treatment. That is a number families and pediatric oncologists will want to see, given that tovorafenib received accelerated approval partly on the strength of response rate and duration, with confirmatory trial data still pending. The safety profile across the full 137-patient set stayed flat since the three-year cutoff: no treatment-related deaths, no additional discontinuations due to treatment-related adverse events, and the same Grade 3 or higher events led by reduced growth velocity at 36 percent and anemia at 14 percent.
The confirmatory burden matters here. Accelerated approval means continued availability depends on verifying clinical benefit in a follow-on trial. The FIREFLY-1 four-year data, while exploratory on the new endpoints, give investigators and regulators a richer durability picture at a median study duration of 52.5 months, which is longer follow-up than most pediatric oncology datasets achieve. Other BRAF-targeted combinations are approved in overlapping BRAF-altered populations,, so the competitive question for tovorafenib centers on its weekly oral dosing and its activity across both fusion and point mutation subtypes. The number to track from here is whether the treatment-free interval median eventually gets reached, and at what month.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
